Precision prevention: The current state and future of genomically guided cancer prevention

Nawal Kassem, Leigh Anne Stout, Cynthia Hunter, Bryan Schneider, Milan Radovich

Research output: Contribution to journalReview article

Abstract

The identification of cancer-predisposing germline variants has potentially substantial clinical impact for patients and their families. Although management guidelines have been proposed for some genes, guidelines for other genes are lacking. This review focuses on the current surveillance and management guidelines for the most common hereditary cancer syndromes and discusses some of the most pivotal studies supporting the available guidelines. We also highlight the gaps in the identification of germline carriers, the cascade testing of at-risk relatives, and the challenges impeding the proper follow-up and optimal management of pathogenic germline carriers. The anticipated surge in the number of identified germline carriers, deficient management guidelines, poor cascade testing uptake, and long-term follow-up necessitate the development of multidisciplinary clinics as an obligatory step toward the improvement of cancer prevention.

Original languageEnglish (US)
Pages (from-to)96-108
Number of pages13
JournalJCO Precision Oncology
Volume3
DOIs
StatePublished - Jan 1 2019

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'Precision prevention: The current state and future of genomically guided cancer prevention'. Together they form a unique fingerprint.

  • Cite this